A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants with Non-Segmental Vitiligo.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503502-37-00

Acronym

MK-6194-007

Enrollment

Registered

2023-12-22

Start date

2024-01-24

Completion date

2025-06-30

Last updated

2025-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non segmental vitiligo

Brief summary

Change from Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24, Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE

Detailed description

Change from Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24

Interventions

DRUGPlacebo to MK-6194

DRUGMK-6194

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24, Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE	—

Secondary

Measure	Time frame
Change from Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24	—

Countries

Belgium, France, Germany, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026